Chugai Pharmaceutical Co., Ltd. (CHGCY)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Osamu Okuda | President, CEO & Representative Director | 1.39M | -- | 1963 |
| Mr. Iwaaki Taniguchi | Executive VP, Head of Finance Supervisory Division, CFO & Director | -- | -- | 1967 |
| Toshiya Sasai | Executive of Investor Relations Group & Corporate Communications Department | -- | -- | -- |
| Mr. Masayoshi Higuchi | VP and Head of Quality, Regulatory Compliance Unit, Business Strategy & Compliance Dept. | -- | -- | -- |
| Junichi Takano | Head of Marketing & Sales Division | -- | -- | -- |
| Mr. Shinji Hidaka | Executive Vice President | -- | -- | -- |
| Mr. Junichi Ebihara | Executive Vice President | -- | -- | -- |
| Dr. Yoshiaki Ohashi | SVP & Full-time Audit Supervisory Board Member | -- | -- | 1960 |
| Mr. Tetsuya Yamaguchi | Executive VP & Head of PHC Solution Unit | -- | -- | -- |
| Mr. Yoshiyuki Yano | Executive Vice President | -- | -- | -- |
Chugai Pharmaceutical Co., Ltd.
- Sector:
- Healthcare
- Industry: Drug Manufacturers - General
- Full Time Employees:
- 7,604
Description
Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company's products for oncology primarily include Avastin, FoundationOne, Polivy, Rozlytrek, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, and Gazyva; Edirol, an Osteoporosis agent; Mircera, an erythropoiesis agent; Oxarol, an agent for secondary hyperparathyroidism; and other diseases comprise Hemlibra, CellCept, Bonviva, Tamiflu, Evrysdi, Ronapreve, Vabysmo, and Enspryng. It has various development product candidates in the areas of oncology, immunology, neuroscience, hematology, ophthalmology, and other diseases. Chugai Pharmaceutical Co., Ltd. has strategic alliances and collaboration with Roche Group. The company was founded in 1925 and is headquartered in Chuo, Japan. Chugai Pharmaceutical Co., Ltd. operates as a subsidiary of Roche Holding Ltd.
Corporate Governance
Upcoming Events
July 25, 2024 at 7:00 AM UTC
Chugai Pharmaceutical Co., Ltd. Earnings Date
Recent Events
December 28, 2023 at 12:00 AM UTC
Ex-Dividend Date
September 16, 2019 at 12:00 AM UTC
Dividend Date